167,095 Shares in PROCEPT BioRobotics Corporation $PRCT Purchased by Osterweis Capital Management Inc.

Osterweis Capital Management Inc. acquired a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 167,095 shares of the company’s stock, valued at approximately $3,773,000. Osterweis Capital Management Inc. owned 0.29% of PROCEPT BioRobotics at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Advisory Services Network LLC grew its holdings in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after purchasing an additional 250 shares in the last quarter. Osaic Holdings Inc. grew its stake in PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after buying an additional 337 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of PROCEPT BioRobotics by 4.7% in the 4th quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock worth $306,000 after buying an additional 438 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of PROCEPT BioRobotics by 1.4% in the 2nd quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock worth $2,848,000 after buying an additional 693 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ:PRCT opened at $21.60 on Wednesday. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $20.36 and a 200-day moving average price of $24.06. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -11.13 and a beta of 0.89. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same period in the previous year, the business earned ($0.35) earnings per share. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, equities analysts anticipate that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of PROCEPT BioRobotics stock in a transaction dated Friday, August 7th. The shares were purchased at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on PRCT shares. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. TD Cowen dropped their price target on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. UBS Group cut PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Finally, Wells Fargo & Company cut PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, PROCEPT BioRobotics has a consensus rating of “Hold” and an average price target of $28.00.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Several law firms, including Hagens Berman, Rosen, Kaplan Fox, Pomerantz, and others, are soliciting investors who purchased PRCT securities between February 28, 2024, and February 25, 2026. Investors have until September 22, 2026, to seek appointment as lead plaintiff. Hagens Berman class-action announcement
• Negative Sentiment: The underlying lawsuit alleges that PROCEPT misled investors about demand and recurring sales trends by using repeated late-quarter bulk discounts to encourage handpiece purchases, potentially inflating reported revenue signals. The complaint also points to weaker-than-expected unit handpiece sales and excess inventory held by customers. These are allegations, and the company’s liability has not been established. Kahn Swick & Foti securities-fraud announcement
• Negative Sentiment: The legal action creates potential costs, management distraction, and continued uncertainty around PROCEPT’s sales practices, inventory levels, and the sustainability of its growth. The concentration of similar investor-alert releases may keep attention on the lawsuit even though the announcements do not represent new operating results or a new company disclosure. Glancy Prongay Wolke securities-fraud deadline alert

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.